Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients

Extraordinary progress has been made over the last decade in the treatment of multiple myeloma with the incorporation of new drugs, particularly proteasome inhibitors, immunomodulators, and monoclonal antibodies.The combined use of innovative drugs, already in the first lines of treatment, has led t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Angelo Maiolino, Luciano J. Costa, Marcelo Pasquini, Edvan de Queiroz Crusoe, Afonso Celso Vigorito, Marco Aurélio Salvino, Fernanda Salles Seguro, Jayr Schmidt Filho, Vania Tietsche de Moraes Hungria
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Multiple myeloma Treatment Immunotherapy CAR-T cells Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/6b4eb551c30a469fa37f117d2387670c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6b4eb551c30a469fa37f117d2387670c
record_format	dspace
spelling	oai:doaj.org-article:6b4eb551c30a469fa37f117d2387670c2021-11-18T04:51:00ZAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients2531-137910.1016/j.htct.2021.09.004https://doaj.org/article/6b4eb551c30a469fa37f117d2387670c2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921001383https://doaj.org/toc/2531-1379Extraordinary progress has been made over the last decade in the treatment of multiple myeloma with the incorporation of new drugs, particularly proteasome inhibitors, immunomodulators, and monoclonal antibodies.The combined use of innovative drugs, already in the first lines of treatment, has led to an expressive increase in the survival of these patients. However, the approach to relapse remains a great challenge, and the disease continues to be incurable. In this scenario, modern immunotherapy has gained the limelight, especially with its recent use of CAR-T cells in clinical trials, as in the case of multiple myeloma, having the BCMA as the primary target.The results are impactful in the treatment of multiple myeloma patients who have had multiple relapses and are triple- and penta-refractory. In this Consensus, we have brought together a group of experts in multiple myeloma to discuss and forward their recommendations for the future, which we hope is very near, incorporating the CAR-T in our country.Angelo MaiolinoLuciano J. CostaMarcelo PasquiniEdvan de Queiroz CrusoeAfonso Celso VigoritoMarco Aurélio SalvinoFernanda Salles SeguroJayr Schmidt FilhoVania Tietsche de Moraes HungriaElsevierarticleMultiple myelomaTreatmentImmunotherapyCAR-T cellsDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S30-S34 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Multiple myeloma Treatment Immunotherapy CAR-T cells Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Multiple myeloma Treatment Immunotherapy CAR-T cells Diseases of the blood and blood-forming organs RC633-647.5 Angelo Maiolino Luciano J. Costa Marcelo Pasquini Edvan de Queiroz Crusoe Afonso Celso Vigorito Marco Aurélio Salvino Fernanda Salles Seguro Jayr Schmidt Filho Vania Tietsche de Moraes Hungria Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
description	Extraordinary progress has been made over the last decade in the treatment of multiple myeloma with the incorporation of new drugs, particularly proteasome inhibitors, immunomodulators, and monoclonal antibodies.The combined use of innovative drugs, already in the first lines of treatment, has led to an expressive increase in the survival of these patients. However, the approach to relapse remains a great challenge, and the disease continues to be incurable. In this scenario, modern immunotherapy has gained the limelight, especially with its recent use of CAR-T cells in clinical trials, as in the case of multiple myeloma, having the BCMA as the primary target.The results are impactful in the treatment of multiple myeloma patients who have had multiple relapses and are triple- and penta-refractory. In this Consensus, we have brought together a group of experts in multiple myeloma to discuss and forward their recommendations for the future, which we hope is very near, incorporating the CAR-T in our country.
format	article
author	Angelo Maiolino Luciano J. Costa Marcelo Pasquini Edvan de Queiroz Crusoe Afonso Celso Vigorito Marco Aurélio Salvino Fernanda Salles Seguro Jayr Schmidt Filho Vania Tietsche de Moraes Hungria
author_facet	Angelo Maiolino Luciano J. Costa Marcelo Pasquini Edvan de Queiroz Crusoe Afonso Celso Vigorito Marco Aurélio Salvino Fernanda Salles Seguro Jayr Schmidt Filho Vania Tietsche de Moraes Hungria
author_sort	Angelo Maiolino
title	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
title_short	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
title_full	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
title_fullStr	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
title_full_unstemmed	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
title_sort	associação brasileira de hematologia, hemoterapia e terapia celular consensus on genetically modified cells. iv: car-t cell therapy for multiple myeloma patients
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/6b4eb551c30a469fa37f117d2387670c
work_keys_str_mv	AT angelomaiolino associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients AT lucianojcosta associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients AT marcelopasquini associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients AT edvandequeirozcrusoe associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients AT afonsocelsovigorito associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients AT marcoaureliosalvino associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients AT fernandasallesseguro associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients AT jayrschmidtfilho associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients AT vaniatietschedemoraeshungria associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsivcartcelltherapyformultiplemyelomapatients
_version_	1718424979900465152

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients

Ejemplares similares